OGN - Organon ObsEva ink ebopiprant licensing deal for preterm labor

TolikoffPhotography/iStock via Getty Images Organon (OGN) and ObsEva (OBSV) have entered into an agreement whereby Organon will license the global development, manufacturing and commercial rights to ebopiprant (OBE022), being evaluated as a potential treatment for preterm labor by reducing inflammation and uterine contractions. Under the terms of the agreement, ObsEva is entitled to receive tiered double-digit royalties on commercial sales as well as up to $500M in upfront and milestone payments including $25M to be paid at signing, up to $90M in in development and regulatory milestones and up to $385M sales based milestones. Ebopiprant (OBE022) was licensed from Merck KGaA, Darmstadt, Germany, in 2015.

For further details see:

Organon, ObsEva ink ebopiprant licensing deal for preterm labor